Strata Skin Sciences announces publication on XTRAC Excimer Laser treatment

STRATA Skin Sciences (SSKN) announces the publication of a new peer-reviewed study in Lasers in Medical Science that reinforces the Company’s commitment to personalized medicine. The study demonstrates that treatment using the Company’s XTRAC 308nm Excimer Laser in combination with 0.1% tacrolimus ointment significantly improves outcomes in patients with plaque-type psoriasis compared to topical monotherapy. The study, titled “Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis,” was authored by Xiaobin Gao, Shuhua Du, Jun Zeng, Yan Li, and Dan Shen and published in Lasers in Medical Science. The retrospective observational study involved 100 adult patients with plaque-type psoriasis treated between January 2023 and January 2024. Patients were divided into two equal groups: Control group, which received 0.1% tacrolimus ointment twice daily for 8 weeks; Observation group, which received the same topical regimen plus phototherapy using the 308 nm Excimer Laser twice weekly, using patient-specific dosing determined by their individual Minimum Erythema Dose. Key Findings: Personalized, Targeted Laser Therapy Enhances Efficacy: PASI Reduction: Control group: Mean PASI dropped from 18.62 to 5.23; Observation group: Mean PASI dropped from 18.36 to 3.30; The difference was statistically significant, showing the combination therapy was markedly superior. Safety Profile: No serious adverse events in either group; Mild and self-resolving irritation or eczema reported in a small number of patients. Personalization in Practice: Individualized excimer laser dosing based on MED and plaque characteristics enabled targeted lesion treatment, maximizing benefit while minimizing exposure to healthy tissue-a fundamental principle of precision dermatology. Mechanistic Synergy: The combination works through complementary immunomodulatory pathways: the excimer laser induces apoptosis in pathogenic T-cells and suppresses keratinocyte hyperproliferation, while tacrolimus locally inhibits cytokine release through calcineurin inhibition. This resulted in faster resolution of plaques and enhanced patient outcomes